Loading company…
Redesign Science is a New York company using its NUVO platform for biomolecular simulation in drug discovery.
Founded in 2017 in New York, US, Redesign Science was co-founded by David Rooklin and Haotian Li. Its NUVO platform combines physics-based molecular dynamics with generative AI to develop small molecule Targeted Protein Interaction Modulators (TPIM). Customers are biopharmaceutical companies and research institutions, which pay licensing fees and support or consultancy fees under multi-year agreements. In December 2021 the company raised USD 10 mn in a Seed round led by Kaitai Capital, with Collaborative Fund, Preface Ventures, Third Kind Venture Capital and ZhenFund participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in